Interestingly, 4.1R null mice display not only the expected hematopoietic phenotype (chronic hemolytic anemia, splenomegaly, spherocytosis and reticulocytosis; (162) ) but also neuro-behavioral deficits, likely resulting from the lack of 4.1R expression in cerebellum, dentate gyrus and hippocampus (70), and a renal phenotype (our unpublished data). Indeed, 4.1R null mice present with a slight urine acidification and alterations in Na/K balance upon water deprivation. More recently, we have reported that 4.1R null red blood cells display hyperactivity of the sodium-proton exchanger NHE1 (163) , of the "Gardos channel" calcium-gated potassium channel (163, 164) and of a potassium-chloride co-transporter (163) . Terada et al. have also suggested an interaction between 4.1B and the sodium bicarbonate co-transporter NBC1 in the PCT based on electron microscopy analysis of kidney sections showing co-localization of the two proteins (72). Taken together, these recent findings provide us with interesting leads as for identifying additional ion transporters interacting with 4.1 proteins in the kidney epithelium.
Renal ezrin
A member of the protein 4.1 superfamily, ezrin, is expressed at high levels at the apical pole of epithelia including kidney (158) (Figure 4 ). Up-regulation of ezrin expression is a hallmark of major kidney diseases such as polycystic kidney disease (165) and nephrogenic diabetes insipidus (166) . Ezrin, in association with PDZ domain containing protein sodium-proton exchanger regulatory factor 2 (NHERF-2), bridges the cytoskeleton and the integral membrane protein podocalyxin in podocytes (167) , disorganization of this link leading to a dramatic loss in glomerular foot processes (168) . A NHERF-2/podocalyxin complex has also been recently characterized in the apical region of MDCK cells undergoing polarization (169) . In a similar fashion, in concert with PDZ domain-containing protein NHERF-1, ezrin has been shown to regulate sodium and phosphate reabsorption and proton secretion at the apical pole of the proximal convoluted tubule through its interaction with the sodium/phosphate co-transporter Npt2 and the sodium proton exchanger NHE3, respectively (170, 171) . Thus, ezrin binds to the cytoplasmic domain of NHE3 but recruits also adapter and signaling molecules, i.e. NHERF-1 and cyclic AMP-dependent protein kinase (PKA) (172) (173) (174) . Recruitment of PKA in the vicinity of NHE3 represents a key event in the regulation of NHE3 exchanger activity. Alterations in ezrin expression and PKA signaling have been observed in polycystic kidney disease (165) .
Co-staining of mouse kidney with an anti 4.1B antibody and either an anti-ezrin or an anti-NHERF-1 antibody illustrates the mutually exclusive expression of renal 4.1 proteins and ezrin or NHERF-1 at the basolateral and apical pole of the kidney epithelium, respectively ( Figure 4 ). This specialized epithelial organization may play an important role in coordination of ion transport. Indeed the level of activity of NHE3 at the apical pole of the TAL epithelium has been demonstrated to depend on the level of activity of NHE1 at the basolateral pole (175) (176) (177) , the integrity of the cytoskeleton being required for this functional link to operate (178) . The potential relevance of this intriguing distribution in control of cell proliferation will be discussed later in this chapter.
Renal ankyrins
Structure and function of renal ankyrins are discussed in another chapter of this issue. We will only emphasize here that, like renal 4.1 proteins: i) renal ankyrins are expressed as products of distinct ankyrin genes at the basolateral pole of the kidney epithelium; ii) these ankyrin gene products actually correspond to various isoforms generated by tissue-specific pre-mRNA splicing events; iii) renal ankyrins show mutually exclusive expression along the nephron; and iv) renal ankyrins mediate proper anchorage of key ion transporters and cell adhesion molecules in the basolateral plasma membrane of the kidney epithelium.
POTENTIAL FUNCTIONS FOR RENAL 4.1 PROTEINS
As a first step to decipher the roles of 4.1 proteins in kidney structure and function, we have begun to identify potential binding partners for kidney 4.1B, kidney 4.1R and kidney 4.1N, through the screening of a rat kidney yeast two-hybrid system cDNA library with full length renal 4.1 proteins (71) and 4.1R CTD baits.
Methodology
A rat kidney yeast two-hybrid system cDNA library, cloned into the GAL4 activation domain vector pGAD3S-2X (179, 180) , was screened for binding partners using baits corresponding to cDNAs encoding full length coding regions of the major kidney-specific isoforms of mouse 4.1N, 4.1R and 4.1B (71), or the C-terminal domain of mouse 4.1R. Baits were cloned into the LexA DNA binding domain vector pLEX12 (179, 180) and used for yeast transformation. Yeast transformed with each pLEX12 bait cDNA, was selected in absence of Tryptophane, then transformed with the pGAD3S-2X rat kidney cDNA library conferring upon yeast growth in absence of Leucine. Yeast was grown on triple selection plates lacking Tryptophane, Leucine and Histidine in order to select clones in which the bait of interest and putative preys interacted with each other. Such proteinprotein interactions restore a fully active GAL4 transcription factor and drive the expression of histidine selection and βgalactosidase reporter genes. Selected clones were further screened for prey interaction with kidney 4.1 protein baits based on standard X-galactose filter assay (179, 180) . β -galactosidase positive clones were then characterized by DNA sequencing using a forward pGAD3S-2X vector specific primer. Interactions were re-confirmed in yeast co-transformed with cDNAs coding for the bait and the prey of interest. Further mapping of the regions in 4.1 proteins responsible for the identified interactions was determined after probing preys with various truncated variants of protein 4.1 FERM and CTD domains. Only relevant clones (i.e. with prey coding sequences in frame) are presented below.
Identification of binding partners for renal 4.1 proteins
The results of our screen to date are summarized in Table I . The predominant binding partners for kidney 4.1B (27/32 clones) and exclusive binding partners for kidney 4.1N (17/17 clones) correspond to three members of the 14-3-3 family of proteins: 14-3-3theta , 14-3-3zeta , and 14-3-3beta. In contrast, these proteins represent a minor category of binding partners for kidney 4.1R (3/16 clones). Another binding partner for kidney 4.1B (5/32 clones) is pICln, a cell swelling-activated chloride channel previously reported to interact with 4.1R (46). Additional potential binding partners for kidney 4.1R include: a putative phosphatase suspected to promote cell proliferation, LRP16 (6/16 clones) (181, 182) ; two proteins involved in trafficking, SEC14L1 (1/16 clones), a mammalian homolog of yeast phosphatidylinositol/phosphatidylcholine transfer protein SEC14 (183) and the Rab GDP-dissociation inhibitor (GDI) Rab-GDIalpha (2/16 clones), a regulatory protein for small GTP-binding Rab proteins that regulates vesicle-mediated cellular transport through control of Rab GDP/GTP exchange reaction and translocation of Rab proteins between the cytosol and cell membranes (184) (185) (186) (187) (188) (189) (190) . Of particular note, a small GTPase of the Rab family has been recently shown to regulate postsynaptic terminal trafficking of AMPA receptors (191) , a class of receptors that has been recently reported to interact with 4.1N and PDZ domain-containing protein SAP 97 (20). Another 4.1R binding partner identified is the beta-Amyloid Precursor Protein (beta-APP) (1/16 clones), a key protein in Alzheimer's disease (AD) pathogenesis (192) . 4.1R may potentially bind to a component of the protein translation machinery involved in cytoskeleton reorganization and cell transformation, i.e. elongation initiation factor 1alpha (2/16 clones) (193, 194) . Lastly, we identified the putative tumor suppressor TMEM24 (195) (1/16 clones), a gene present in the 11q23.3 locus and frequently deleted in neuroblastomas, as a potential binding partner for 4.1R.
While it will be important to confirm the various protein-protein interactions identified by other methodological approaches, some of them have been previously documented in the literature. As such, we will focus our discussion on the following three classes of binding partners: beta-APP, 14-3-3 proteins, and the cell swelling-activated chloride channel pICln.
β-Amyloid Precursor Protein: a key element in progression of neuropathies and potentially epitheliopathies
Progressive cerebral deposition of the amyloid beta-peptide (A-beta peptide) is an early and invariant feature of Alzheimer's disease (196) . This peptide originates from proteolytic cleavage of the very C-terminal region of the beta-amyloid precursor protein (beta-APP), a widely expressed membrane-spanning glycoprotein. Normal secretion of beta-APP involves proteolytic cleavage, releasing the soluble extramembranous portion and retaining a 10kD C-terminal fragment in the membrane. Another proteolytic processing pathway involves reinternalization of mature beta-APP from the cell surface and its targeting to endosomes/lysosomes. Subsequent proteolytic cleavage of mature beta-APP in the late Golgi and/or endosomal compartment leads to secretion of small peptides, including the 4kD A-beta peptide, into the extracellular milieu. Mutations in beta-APP have been shown to promote its proteolysis, resulting in the hypersecretion of A-beta peptide by cells, a pre-symptomatic event in AD pathogenesis.
Accumulation of the A-beta peptide occurs not only in the brain but also in the abluminal basement membrane of brain microvessels (197) and, potentially, in epithelia, such as kidney. Indeed, the Madin Darby canine kidney (MDCK) cell line has been used to study beta-APP sorting and processing (196) (197) (198) (199) . A Tyr residue (Tyr 653 ) and the immediately adjacent residues (654-664) in the C-terminal region of beta-APP have been shown to dictate proper basolateral sorting of the protein and secretion of the A-beta peptide in MDCK cells. Importantly, basolateral secretion of A-beta peptide in MDCK cells is disturbed by alterations of intracellular pH and by the introduction of a mutation in beta-APP associated with familial Alzheimer's disease. However, the impact of the accumulation of the A-beta peptide in the basement membrane of epithelia, including the kidney epithelium, of AD patients has not been fully evaluated.
Interestingly, 4.1R has been previously reported to co-localize with neurofibrillary tangles in brain lesions of patients presenting with AD (200) . It must be emphasized that, at the time of this discovery, none of the three protein 4.1 homologs were characterized and that the antibody used in this study may have possibly cross-reacted with other 4.1 homologs, since all four 4.1 proteins are expressed in brain (66, 70) . Moreover, neurofibrillary tangles have been reported to be enriched in 14-3-3zeta (201), one of the 14-3-3 isoform identified as a binding partner for kidney 4.1B and 4.1N in our screening ( Table I ). The observation that 4.1R null mice display some neuro-behavioral deficits (70) highlights the importance of 4.1 proteins in brain physiopathology.
Our yeast two-hybrid screening has identified the very last nine C-terminal amino acids of beta-APP (Y 687 KFFEQMQN) as the binding motif for 4.1R. Although this motif is located downstream of the region required for proper sorting of beta-APP and secretion of the A-beta peptide, one may speculate that 4.1R, and/or its homologs, could facilitate beta-APP anchorage in the basolateral membrane of various epithelia, including kidney. One may also speculate a role for 4.1R in basolateral secretion of the A-beta peptide since there is now clear evidence for the presence of a cytoskeletal network, including protein 4.1 homologs, on the cytoplasmic face of the Golgi apparatus and intracellular vesicles (4, 60-62, 202, 203) .
Lastly, it is worth highlighting that beta-APP metabolism is stimulated by metabotropic glutamate receptors (204) and that its processing is regulated by these receptors in hippocampal neurons (205) , a region of the brain where several protein 4.1 homologs are detected (66) . Strikingly, metabotropic glutamate receptors have been recently reported to interact with 4.1G (17) and may potentially interact with other protein 4.1 homologs as well. Further studies are needed to determine whether protein 4.1 plays an important role in beta-APP metabolism and cell sorting in brain as well as in epithelia, and whether alterations in protein 4.1 expression either facilitate or impair the progression of beta-APP-related pathologies such as AD.
Cell signaling: importance of 14-3-3 proteins
As detailed earlier, several protein-protein interactions involving protein 4.1 FERM domain have now been extensively documented ( Figure 2 ). The recent characterization of an interaction between 4.1B FERM domain and members of the family of 14-3-3 proteins adds to the diversity of protein complexes organized around the FERM domain (117) . Interestingly, 4.1R FERM domain appears to interact weakly with 14-3-3 proteins  compared to 4.1B and 4.1G FERM domains. A Phe residue (Glu-Gln-Phe 359 -Glu) is necessary for 4.1B FERM domain interaction with 14-3-3epsilon, 14-3-3eta and  14-3-3gamma (50). Alignment of the four 4.1 protein FERM domains revealed that this Phe residue is conserved in 4.1B, 4.1G and 4.1N but not in 4.1R where it is replaced by a Tyr residue ( Figure 2 ). Importantly, a Phe 359 ->Tyr mutation in 4.1B FERM domain impairs its interaction with 14-3-3 proteins, providing a mechanistic explanation for the weak interaction of 4.1R with 14-3-3 proteins.
Our yeast two-hybrid system screening showed that 14-3-3 proteins are major binding partners for 4.1N. The conservation of the key Phe 359 residue in 4.1N FERM domain supports further the likeliness of interactions between 4.1N and 14-3-3 proteins in vivo. Interestingly, the repartition of 14-3-3 clones differs between kidney 4.1N and kidney 4.1B. Indeed, 14-3-3 beta appears as the major binding partner for kidney 4.1N, while 14-3-3theta is the predominant binding partner for kidney 4.1B (Table I ). It is likely that variations in amino acids surrounding the canonical Phe 359 residue account for preferential interactions between specific 14-3-3 and protein 4.1 isoforms. It should be noted that the subset of 14-3-3 protein isoforms (14-3-3beta, theta and zeta) that we identified to interact with 4.1 proteins are different from those identified by Yu et al. (117) , i.e. 14-3-3 epsilon, eta and gamma. This may reflect tissue-specific expression of subsets of 14-3-3 isoforms. The observations emphasized above, i.e. distinct proportion of 14-3-3 clones among binding partners for each renal 4.1 protein and distinct repartition of the 14-3-3 isoform species interacting with kidney 4.1N and 4.1B, illustrate the functional specialization of 4.1 proteins despite the high level of conservation of key functional domains.
The defining of an interaction between 4.1B FERM domain and a member of the 14-3-3 family of proteins, 14-3-3 epsilon (117), provides an important clue to deciphering novel mechanisms by which protein 4.1 may control cell signaling and cell proliferation. The 14-3-3 family of proteins consists of adapter proteins with multiple functions (206) : regulation of cell cycle (207, 208) , cell growth (209) , apoptosis (210) , transcription, nuclear trafficking (211), protein sorting (212, 213) , signal transduction (214) (215) (216) (217) (218) (219) , cell polarity (220) (221) (222) (223) and cytoskeletal structure (224) (225) (226) . As disruption of interaction of some 14-3-3 proteins with 4.1B FERM domain does not impair 4.1B anti-proliferative properties (50), the precise function(s) of protein 4.1 interactions with 14-3-3 proteins still remain(s) to be defined.
For example, protein 4.1-dependent recruitment of 14-3-3 proteins could participate in regulation of activities of transmembrane proteins such as ion channels and calcium pumps (227) . A recent study has unveiled a novel role for 14-3-3 proteins in mediating downregulation of Na,K-ATPase activity upon stimulation of kidney cells by dopamine, 14-3-3 proteins recruiting PI3-kinase to the site of Na,K-ATPAse endocytosis (228) . The location of the 14-3-3 binding motif in 4.1 FERM domain suggests potential binding competition of 14-3-3 proteins with neighboring binding partners of 4.1 FERM domain, such as calmodulin or PDZ domain-containing proteins (12, 19, 31, 111) , depending on the cell context ( Figure 2 ). Some of these dynamic interactions could be either favored or inhibited upon cell activation. Indeed, cell activation leads to an increase in cytosolic calcium concentration and in changes in protein phosphorylation levels, both events modulating protein 4.1 interactions with its binding partners (1, 24, 37, 111, 137, (229) (230) (231) (232) . Finally, interactions of selected 4.1 proteins with 14-3-3 isoforms could participate in the organization of other protein complexes located in cellular compartments other than the plasma membrane (233) . One of those components could be the centrosome where protein 4.1 and 14-3-3 homologs have been detected (38, 39, 42, 45, 233, 234).
5.5.. Regulation of cell volume in response to osmotic stress: role of the cell swelling-activated chloride channel pICln 5.5.1. Mechanisms of regulation of cell volume
Regulation of cell volume is a critical function in kidney where the epithelium environment is characterized by very different ionic compositions, depending on the segment of the nephron (235) . Defective cell volume regulation leads to major nephropathies (236, 237) . Changes in cell volume are accompanied by a reorganization of the actin cytoskeleton which is associated with membrane ion transporters, the cytoskeleton acting as both a structural network and a sensor for cell volume changes. Cells maintain a constant volume despite variations in concentrations of salts in their surroundings through either Regulatory Volume Increase (RVI), activated when cells shrink, or Regulatory Volume Decrease (RVD), activated when cells swell.
Two types of transporters mediate RVI, the Na,K,2Cl co-transporter BSC1 and the sodium proton exchangers NHE1, NHE2 and NHE4 (238) (239) (240) . The reorganization of the actin cytoskeleton plays an important role in NaCl entry into the cell through activation of these membrane channels (241) (242) (243) . In an hypotonic environment, cells undergo RVD as a result of a loss of K and Cl, mediated by activation of a K,Cl co-transporter (244) . This ion efflux drives an outward movement of water molecules and subsequently a decrease in cell volume. An outward current of chloride involving also other osmolytes, known as I swell , is involved in RVD as well (245) . Several cell swelling-activated proteins have been proposed to account for the I swell current: chloride channels C1C-2 and C1C-3, P-glycoprotein, and, importantly in the context of this review, the chloride channel pICln.
Properties of the cell swelling-activated chloride channel pICln 5.5.2.1. pICln: a versatile protein
pICln is an ubiquitous protein essential for cell viability (246) . Its over-expression results in an increase in an outward Cl conductance, while its down-regulation leads to a delay and decrease in RVD (247) (248) (249) (250) . pICln therefore plays a critical role in RVD, a function that is altered in major nephropathies. pICln has been identified in reticulocytes and in young red blood cells where it accumulates in the plasma membrane through an interaction with the actin cytoskeleton (251) . In platelets, pICln associates with the alpha2-beta3 integrin and regulates platelet function (252) . In kidney, pICln is detected predominantly in the cytosol of all regions of the nephron (253) . In addition, it is detected at the apical pole of the epithelium in the cortex, and at both basolateral and apical poles in the medulla (253) . While it is primarily present in the cytosol of resting cells, it is targeted to and inserted into plasma membrane in response to cell swelling and to diuretics (253, 254) . Once inserted into the membrane, pICln forms a channel-like structure enabling efflux of Cl and other osmolytes, and therefore RVD.
The mechanism by which pICln is targeted to the membrane is still unknown (253) . However, the carboxyl terminus of pICln has been shown to bind to 4.1R FERM domain, suggesting a potential involvement of 4.1R in regulation of cell volume through proper membrane anchorage of pICln (46). Moreover, pICln binds to actin (251) , to a non-muscle isoform of myosin light chain (255) , and to a mammalian homolog of yeast Skb1 (256) . Importantly, Skb1 has been shown to control cell volume in yeast (257) , through cytoskeletal rearrangement mediated by its interaction with the p21 Cdc42/Rac activated protein kinase Shk1 (258) . In summary, pICln is involved in distinct cellular processes including regulation of cell volume, cell morphology, cytoskeleton architecture, cell cycle and RNA processing. Thus defining of the functional relevance of pICln/4.1 interaction in various cellular structures is an important goal of future studies.
Characterization of pICln/4.1 interaction Protein 4.1 in kidney physio-pathology

First Galley
Protein pICln has been previously reported to interact in vitro and in vivo with 4.1R FERM domain (46). However, the recent characterization of pICln distribution in rat kidney suggests that pICln may interact with other 4.1 proteins since it is expressed in regions of the nephron where 4.1 proteins other than 4.1R are present (71).
Interestingly, we identified pICln as a binding partner for kidney 4.1B (Table 1) . As shown in Figure 5 , additional binding assays performed in yeast revealed that full length kidney 4.1R (panel A1), kidney 4.1B (panel A4), kidney 4.1N (panel B1), their respective FERM domains (panels A2, A5 and B2), as well as 4.1G FERM domain (panel A6) all interact strongly with pICln. pICln interaction with each renal 4.1 protein may be therefore functionally relevant. Moreover, serial truncations of 4.1N FERM domain (panels B3-B6) enabled us to narrow down the minimal region in 4.1N FERM domain required for interaction with pICln to a peptide encompassing amino acids 162-280. A previous study reported that a slightly larger region of 4.1R FERM domain encompassing amino acids 136-283 was necessary for interaction with pICln (46). This region corresponds to the Cterminal half of the FERM domain. As proposed earlier for 14-3-3 proteins, the regulation of pICln binding to protein 4.1 FERM domain may also depend on the dynamic regulation of interactions of neighboring binding partners, in particular PDZ domain containing proteins and calmodulin ( Figure 2 ).
Validation of the novel protein 4.1-mediated protein-protein interactions described above in vivo will rely primarily on: i) investigation of the phenotypes resulting from protein 4.1 gene silencing in relevant kidney epithelial cells, cells downregulated for protein 4.1 expression being expected to display mis-localization of binding partners, impact on 14-3-3-mediated cell signaling, metabolism of beta-APP and cell response to osmotic stress; ii) confirmation of the phenotypes unveiled through this cell based-strategy in mouse knock out models for each protein 4.1 gene as they will become available to us. Deciphering such phenotypes will be greatly facilitated by the rapid progress in microarray-based renal systems biology (259) . Such an approach will enable us defining signatures as for alterations in transcriptional activity and in transduction pathways in cell lines subjected to protein 4.1 gene silencing and in protein 4.1 null mouse kidneys.
PROTEIN 4.1 AND EZRIN: KEY PLAYERS IN CONTROL OF CELL PROLIFERATION
As described earlier in this review, major kidney pathologies have been linked to ezrin over-expression. To date, none have been related to alterations in levels of protein 4.1 expression despite the presence of several members of the protein 4.1 family in the nephron. We anticipate that protein 4.1-related kidney diseases, resulting from protein 4.1-dependent defects in membrane anchorage and/or protein processing as suggested here for AD, will be characterized in the near future. Such kidney diseases will very likely include proliferative diseases. Indeed, anti-proliferative properties have been extensively documented for 4.1B (51, 53), and to a lesser extent for 4.1R (48, 49) and 4.1N (260) (261) (262) . Loss of heterozygosity (LOH) of 4.1B and 4.1R genes has been implicated in progression of subsets of ependymomas and meningiomas (48, 49). Some lung and breast carcinomas are also characterized by LOH and/or hypermethylation of the 4.1B gene (263) . Protein 4.1B could exert its anti-proliferative effect through inhibition of protein arginine N-methyltransferase 3 activity (52). Importantly, 4.1B over-expression in proliferative neuronal cells blocks their growth (264) . In a similar fashion, we have recently established that over-expression of a kidneyspecific isoform of 4.1N, in a kidney epithelial cell line that normally expresses this isoform, leads to cell arrest (260). Two reports have described a concomitant loss of 4.1B and E-cadherin in cell-cell contact regions upon transition from adenoma to carcinoma in pancreas and colon epithelia (53, 73) . We therefore predict that the loss of expression of renal 4.1 proteins could lead to proliferative diseases affecting primarily regions of the nephron where each 4.1 protein is solely expressed, i.e. PCT upon loss of 4.1B expression, TAL upon loss of 4.1R expression and DCT and collecting duct upon loss of 4.1N expression.
Several proteins that have been previously described as binding partners for 4.1 proteins, and other potential binding partners that co-distribute with 4.1 proteins in the lateral domain of epithelial cells, likely participate in the formation of elaborate protein complexes responsible for cell-cell adhesion and contact inhibition. They include i) cell adhesion molecules CD44, TSLC1 and the E-cadherin/beta-catenin/alpha-catenin complex (23, 147, 265, 266) ; ii) the sodium-proton exchanger NHE1 (267); iii) PDZ-domain containing proteins dlg (SAP 97) and CASK (29, 31); and iv) cytoskeletal proteins such as spectrin elf (268) . Alterations in activities of the small GTP-binding proteins Rac and RhoA have been proposed to initiate the disorganization of actin filaments observed in proliferative epithelia (269) . Alterations in the actin cytoskeleton would in turn lead to the loss of adhesive protein complexes responsible for epithelial cell interactions through their lateral domains. It remains to be established whether the depolymerization of actin filaments is sufficient to induce disorganization of cell adhesion protein complexes or whether the loss of protein 4.1 in plasma membrane represents a key event in triggering such a disorganization.
The concept that the Four.1/Ezrin/Radixin/Moesin (FERM) domain, a highly conserved peptide among members of the protein 4.1 superfamily, mediates regulation of cell proliferation (270) , has been recently challenged. Indeed, a recent study has established that the unique region U2 of 4.1B is actually responsible for inhibition of cell growth, the FERM domain-dependent anchorage of the U2 region to the plasma membrane representing a necessary event for inhibition of cell proliferation (51). Other mechanisms of control of cell proliferation mediated by protein 4.1 have been proposed. Thus, 4.1N nuclear translocation, occurring upon rat pheochromocytoma PC12 cell differentiation induced by nerve growth factor (261), has been shown to block cell proliferation through interaction of 4.1N CTD with the phosphatidylinositol-3 (PI-3) kinase enhancer PIKE, this interaction resulting in an inhibition of PIKE (262) . A similar inhibition of PI-3 kinase through interaction of the tumor suppressor merlin with PIKE has been recently reported (271) . It is likely that the FERM domain, the unique region U2 and the CTD domain of 4.1 proteins fulfill complementary functions in control of cell proliferation. In contrast with the loss of protein 4.1 expression observed in proliferative tissues, ezrin has been shown to be rather over-expressed upon tumorigenesis (272, 273) . Furthermore, ezrin has been proposed to facilitate cell invasiveness and consequently to play a crucial role in metastasis (274) (275) (276) . Ezrin's metastatic property could result from its ability to activate the PI-3 kinase/AKT survival pathway (277) , Rac1-and Rasdependent pathways (278, 279) and the TOR/S6 kinase/4EB1 pathway (280) .
An intriguing observation is the dramatic change in activities of signaling molecules such as RhoA and Rac, and of adhesion molecules such as CD44 or NHE1, depending on the cell context, i.e. arrested vs. proliferative cells. This so-called cell context would actually depend in a large part on the cross-talk between the extracellular matrix and the cell (281) , this cross-talk having a big impact on the characteristics of plasma membrane protein complexes interacting with the cytoskeleton. Indeed, the proliferative cellular microenvironment mimics a serum deprivation that confers increased cell motility and invasion in breast cancer cells by activating NHE1 (282) . NHE1 activation and the subsequent invasive phenotype of metastatic human breast cells appears to be coordinated by a sequential RhoA/p160ROCK/p38MAPK signaling pathway gated by direct PKA-dependent phosphorylation and inhibition of RhoA. The authors suggest that serum deprivation dynamically remodels the cell and compartmentalizes the signal module described above in leading-edge pseudopodia suggesting a topographic relation of key signaling protein complexes to an invasion-specific cell structure. The disorganization of physiological protein 4.1-based cytoskeletal complexes and the resulting formation of pathological ezrin-based cytoskeletal complexes (283) could play a key role in cell proliferation and invasiveness, by altering irreversibly key signaling cues such as the PKA-gated RhoA/p160ROCK/p38MAPK signaling pathway. In support of this hypothesis, a member of the protein 4.1 superfamily, moesin, has been recently shown to participate in epithelial organization and regulation of cell proliferation through inhibition of Rho activity, thus promoting actin polymerization (284) . Other pathways could be involved as well. Thus, the Drosophila protein 4.1 homolog, coracle, has been initially discovered as a dominant suppressor of the Drosophila EGF receptor homolog (28). The concept that cytoskeletal proteins can have a direct impact on cell signaling has been reinforced by an elegant study establishing a crucial role for spectrin elf, an homolog of red cell beta-spectrin, in regulation of the Transforming Growth Factor-alpha signaling pathway, through proper sorting of two key transducers of this pathway, Smad3 and Smad4 (268) . These findings challenge the paradigm that members of the protein 4.1 superfamily act primarily as structural proteins by providing increasing evidence for a key role of these proteins in cell signaling through proper positioning of regulatory molecules.
The role of 4.1 proteins as tumor suppressors may also result from the ability of these proteins to maintain proper cell volume and intracellular homeostasis through the regulation of ion transporters they interact with, i.e. NHE1 and pICln. Indeed, there is now clear evidence that proliferative cells display an increase in cell volume and intracellular alkalinization (285, 286) . The loss in protein 4.1 expression observed upon epithelial tumor progression, could lead to mis-localization and deregulation of key ion transporters that normally interact with protein 4.1. Thus, NHE1 could become hyperactive in absence of protein 4.1, resulting in an increase in NaCl reabsorption and in proton secretion, i.e. intracellular alkalinization. Such an hypothesis is supported by a recent observation highlighting NHE1 hyperactivity in 4.1R null red blood cells (163) . Although the functional relevance of an interaction between another member of the protein 4.1 superfamily, ezrin, and NHE1 has been extensively documented in fibroblasts, the occurrence of this interaction in normal epithelia is unlikely given the mutually exclusive expression of NHE1 and ezrin, at the basolateral and apical poles, respectively (165, 267) . Based on protein 4.1 and NHE1 codistribution in the lateral domain of epithelia, on the presence of a potential juxta-membrane protein 4.1 binding motif (VKKKQ) in NHE1 cytoplasmic domain and on functional alterations of NHE1 in 4.1R null red blood cells (163) , we are currently investigating whether 4.1R and its homologs are indeed relevant binding partners for NHE1 in kidney epithelium. We speculate that, upon loss of cell polarity and loss of protein 4.1 expression, an interaction between NHE1 and ezrin would be favored and could potentially participate in tumor progression ( Figure 6 ). Dissecting the protein complexes organized around ezrin and transmembrane proteins NHE1 and CD44 would likely lead to an understanding of how ezrin promotes cell motility (287) . A major challenge will be to understand the mechanisms governing distinct cellular distribution and opposite effects on cell proliferation for protein 4.1 and ezrin, despite some structural and functional homology of these two cytoskeletal proteins.
CONCLUSION
Much remains to be done to define the actual involvement of cytoskeletal protein 4.1-and ezrin-based networks in kidney function and the mechanisms by which they fulfill these functions in various parts of the nephron. In particular, we need to further our understanding of the relationships between cytoskeleton-dependent positioning of key transmembrane and adapter proteins and cell signaling wiring and of the consequences of alterations of the cytoskeleton on those processes. The generation of mouse knock out models for each of the four protein 4.1 genes will be instrumental in evaluating the impact of a selective loss of protein 4.1 expression in vivo and in assessing the occurrence of compensatory mechanisms through up-regulation of non targeted 4.1 proteins and/or other members of the protein 4.1 superfamily, such as the ERM proteins.
A major challenge of future investigation will be to decipher the mechanisms responsible for the highly selective expression of spliceforms arising from closely related cytoskeletal protein genes in specialized regions of a given tissue and to evaluate the physiological implications of such an elaborate sorting. Such mechanisms likely involve a well orchestrated network of tissue-and cell-specific transcriptional and signaling events. Their characterization will represent a breakthrough in the cytoskeleton field and will without a doubt further our understanding of the functional links between tissue architecture and physiology. As emphasized by Mohler and Bennett in the chapter related to ankyrins, it will be crucial in that respect to choose appropriate cell and animal models to decipher this fascinating machinery. Figure 2 . Mapping of the binding motifs for various binding partners in protein 4.1 FERM domain. We have highlighted known binding motifs for various binding partners in protein 4.1 FERM domain to illustrate the close proximity of these motifs and therefore the possibility of steric competition depending on cellular context. A Glu-Glu-Asp (EED) motif highlighted in red in exon 5-encoded peptide mediates interaction with anion exchanger AE1 (95) . A 47 mer peptide encoded by exon 8, highlighted in purple, mediates 4.1 interaction with glycophorin C (24). Exon 9-and 11-encoded peptides highlighted in green mediates 4.1 interaction with calmodulin (111) . Exon 10-encoded peptide highlighted in blue mediates 4.1 interaction with tubulin (116) and with PDZ domain-containing proteins p55 (111) and likely dlg (SAP 97) and CASK. A large peptide encompassing exons 9-11 (underlined in the sequence) is necessary for 4. Protein-protein interaction was monitored using a standard X-Gal filter assay. +++: very strong interaction, ++: strong interaction, -: no interaction. Figure 6 . Reorganization of plasma membrane protein complexes upon epithelial cell proliferation. In a normal polarized epithelial cell, CD44, and potentially NHE1, are anchored in the lateral domain through their interaction with 4.1 proteins and the actin cytoskeleton. PDZ domain-containing proteins, such as dlg and/or CASK, would be also recruited in such complexes through interactions with 4.1 proteins (left panel). Ezrin interacts with apical transmembrane proteins such as NHE3 and recruits PDZ domain-containing proteins such as NHERF-1. Ezrin is therefore unable to interact with CD44 and NHE1 due to the mutually exclusive expression of those proteins in a different cell compartment, i.e apical pole vs. basolateral pole. Upon tumorigenesis, protein 4.1 is lost leading to disorganization of protein complexes present in lateral cell-cell contact regions and loss of cell polarity. In contrast, ezrin and its binding partner NHERF-1 become overexpressed and can now associate with CD44 and NHE1 since the localization of these proteins is no longer mutually exclusive within the plasma membrane (right panel). The formation of these novel interactions, in concert with alterations in cell microenvironment, would result in alterations of CD44 and NHE1 properties (as illustrated by changes in color patterns of those proteins between the left and the right panels) and in the formation of protein complexes that would promote cell proliferation and cell invasiveness. We speculate that a similar mechanism would occur in most proliferative epithelia, and in particular in kidney. 3/17 FERM 14-3-3zeta 2/17 FERM The number of clones refers to the number of clones corresponding to the prey of interest relative to the total number of relevant clones pulled out with the bait. A total of 8 10 6 , 33 10 6 and 27 10 6 Trp (+) Leu (+) yeast clones were obtained for kidney 4.1B, kidney 4.1R and kidney 4.1N baits, respectively. Among those, 237, 578 and 415 clones were β-galactosidase (+) Trp (+) Leu (+) His (+), respectively. We have screened so far 74, 100 and 65 clones, respectively. Prior to screening of the library, we
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